Health Trials

Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)

ConditionsSmall Cell Lung Cancer Extensive StageBrain MetastasesSolid Tumor, AdultThoracic CancerSarcoma,Soft TissueHNPCC
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Texas Southwestern Medical Center

About this trial

To characterize feasibility, safety, and/or preliminary efficacy of personalized strategies to adapt standard radiotherapy treatments to individual patient responses.

Eligibility criteria

Qualifiers

>=18 years old

Performance status ECOG 0-2

Extensive stage small cell lung cancer diagnosed by tissue biopsy within 180 days of registration.

Patient must be planned for or receiving standard of care chemoimmunotherapy.

Disqualifiers

Prior whole brain Radiotherapy

Prior surgical resection or focal radiotherapy of a target brain metastasis

Leptomeningeal disease

Unresectable or metastatic (nodal or distant) disease

Trial design

Treatments tested in this trial

  • Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy)
  • Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy)
  • Cohort C: Sarcoma Pre-Operative PULSAR
  • Cohort D: Resectable Head & Neck Squamous Cell Carcinoma (HNSCC) PULSAR/SAbR

Treatment groups

105 Participants
are divided into 4 treatment groups

Sponsors and collaborators

University of Texas Southwestern Medical Center

Lead sponsor

Source ClinicalTrials.gov